These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 26939575

  • 1. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, Sanui M, Takimoto K, Mayumi T, Ono K, Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group.
    Thromb Haemost; 2016 Jun 02; 115(6):1157-66. PubMed ID: 26939575
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
    Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H.
    J Thromb Haemost; 2015 Jan 02; 13(1):31-40. PubMed ID: 25393713
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T.
    Intensive Care Med; 2013 Apr 02; 39(4):644-52. PubMed ID: 23361628
    [Abstract] [Full Text] [Related]

  • 4. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, Inoue Y, Fujimi S, Tanaka H, Hamasaki T, Shimazu T.
    Crit Care; 2015 Mar 03; 19(1):78. PubMed ID: 25883031
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K, Hongo T, Tahira A, Niimi N, Haisa I, Kawakami Y.
    Biol Pharm Bull; 2021 May 01; 44(5):605-610. PubMed ID: 33612566
    [Abstract] [Full Text] [Related]

  • 9. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D, Chikamoto A, Miyanari N, Ohara C, Kuramoto M, Horino K, Ohshima H, Baba H.
    J Surg Res; 2015 Aug 01; 197(2):405-11. PubMed ID: 25972310
    [Abstract] [Full Text] [Related]

  • 10. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A, Tanaka N, Uemura T, Matsuda W, Kimura A.
    BMJ Open; 2016 Dec 30; 6(12):e012850. PubMed ID: 28039291
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T.
    Crit Care; 2011 Dec 30; 15(3):R123. PubMed ID: 21569368
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Mori N, Yamagishi Y, Iwamoto T, Mikamo H.
    Thromb Res; 2023 Jun 30; 226():165-172. PubMed ID: 37182388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N, Goto K, Ohchi Y, Abe T, Koga H, Kitano T.
    J Crit Care; 2016 Dec 30; 36():29-34. PubMed ID: 27546744
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover-AC study).
    Ogura T, Eguchi T, Nakahara K, Kanno Y, Omoto S, Itonaga M, Kuroda T, Hakoda A, Ikeoka S, Takagi M, Okada A, Sato J, Morita R, Michikawa Y, Ito K, Koshita S, Takenaka M, Kitano M, Koizumi M, Higuchi K.
    J Hepatobiliary Pancreat Sci; 2023 Feb 30; 30(2):221-228. PubMed ID: 34021720
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
    Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T.
    J Thromb Haemost; 2015 Apr 30; 13(4):508-19. PubMed ID: 25581687
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis.
    Zhang C, Wang H, Yang H, Tong Z.
    Am J Emerg Med; 2016 Sep 30; 34(9):1876-82. PubMed ID: 27452884
    [Abstract] [Full Text] [Related]

  • 20. Recombinant Human-Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients With Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset.
    Yoshihiro S, Sakuraya M, Hayakawa M, Ono K, Hirata A, Takaba A, Kawamura N, Tsutsui T, Yoshida K, Hashimoto Y.
    Shock; 2019 Feb 30; 51(2):174-179. PubMed ID: 29596106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.